skip to the main content

Boditech Med has entered into a license agreement with SphingoTec

- Worldwide licensing agreement signed to develop and offer penKid as test on Boditech's POCT immunoassay analyzers
- About 13.2 million new cased of acute kidney injury occur every year around the world
- Strengthening collaboration with SphingoTec on severe diseases

Boditech Med plans to strengthen its product line for patients with advanced diseases.

We are delighted to announce that Boditech Med has entered into a non-exclusive royalty-bearing license agreement with SphingoTec for kidney function biomarker Proenkephalin A 119-159(penKid).

Under the terms of this agreement, Boditech Med has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma™ Point of Care platforms. SphingoTec has a monopoly on the penKid, a unique biomarker for real-time assessment of kidney function. Especially, the penKid rapidly provides physicians at the ED and ICU with urgently needed information on kidney function. Through this partnership, Boditech and SphingoTec will make the biomarker penKid available on Boditech Med's worldwide installed base with the goal of improving the management of patients suffering from acute kidney injury (AKI).

Acute kidney injury is a disease in which kidney function rapidly deteriorates, and about 13.2 million new patients occur every year around the world. In addition, as the patients are diagnosed with acute kidney injury after their kidney function has dropped by 50%, there has been an increasing demand for the POC solution.

Boditech Med is planning to strengthen collaboration with SphingoTec focusing on serious illness. SphingoTec is a Hennigsdorf-based integrated diagnostics company providing innovative biomarkers such as acute heart failure and acute kidney injury. The company also has a monopoly on sepsis.

Jörg Menten, CEO, SphingoTec said "Boditech is a leader in point of care diagnostics with a strong global footprint. The agreement entered into with Boditech marks a significant milestone in SphingoTec's mission to provide early detection of acute kidney injury to the international acute and critical care community. Our scientific research shows the future potential of penKid to monitor kidney function in further clinical settings such as renal replacement therapy (3) and pediatric AKI management (4,5). We are excited to work with our new partner to bring these advancements to critical care physicians around the globe very soon."

Eui-Yul Choi, CEO of Boditech Med said "Expanding our critical care portfolio with innovation in the field of acute diseases can, in the future, support our customers applying medical advancements and improve patient outcomes. After successfully evaluating the feasibility of penKid on our diagnostic solutions, we are looking forward to working with SphingoTec for the development and commercialization of the new test."